Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo

Autor: Muller, T. H., Su, C. A. P. F., Weisenberger, H., Brickl, R., Gerhard Nehmiz, Eisert, W. G.

Publikováno v: Scopus-Elsevier

1. In a randomized, double-blind trial we compared the inhibition of the platelet-vessel wall interactions in whole blood ex vivo. There were four groups of 24 healthy volunteers each of whom were treated orally for 3.5 days with either 200 mg dipyri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::cd5fe7768e3e64833fdfef23921a83e2
https://europepmc.org/articles/PMC1368216/

Dipyridamole bioavailability in subjects with reduced gastric acidity.

Autor: Derendorf H, VanderMaelen CP, Brickl R, MacGregor TR, Eisert W

Publikováno v: Journal of Clinical Pharmacology; Jul2005, Vol. 45 Issue 7, p845-850, 6p

Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.

Autor: Offman E; Clinical Pharmacology Sciences, Celerion, 100 Boulevard Alexis-Nihon, Bureau (Suite) 360, Montreal, QC, H4M 2N8, Canada. elliot.offman@celerion.com, Schobelock MJ, Brickl R, VanderMaelen CP, Ehrlich J, Eisert W

Publikováno v: American journal of cardiovascular drugs : drugs, devices, and other interventions [Am J Cardiovasc Drugs] 2013 Apr; Vol. 13 (2), pp. 113-20.

Design and Optimization of a Nanoparticulate Pore Former as a Multifunctional Coating Excipient for pH Transition-Independent Controlled Release of Weakly Basic Drugs for Oral Drug Delivery.

Autor: Chang, Hao Han R.¹ (AUTHOR), Chen, Kuan¹ (AUTHOR), Lugtu-Pe, Jamie Anne¹ (AUTHOR), AL-Mousawi, Nour^1,2 (AUTHOR), Zhang, Xuning¹ (AUTHOR), Bar-Shalom, Daniel² (AUTHOR), Kane, Anil³ (AUTHOR), Wu, Xiao Yu¹ (AUTHOR) sxy.wu@utoronto.ca

Publikováno v: Pharmaceutics. Feb2023, Vol. 15 Issue 2, p547. 21p.

Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men.

Autor: Müller TH; Department of Biological Research, Dr Karl Thomae GmbH, Biberach, Germany. ckmthm@nord.de, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J

Publikováno v: Circulation [Circulation] 1997 Aug 19; Vol. 96 (4), pp. 1130-8.